[{"address1": "180 North LaSalle Street", "address2": "Suite 1600", "city": "Chicago", "state": "IL", "zip": "60601", "country": "United States", "phone": "844 445 5704", "website": "https://www.xerispharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 377, "auditRisk": 7, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 2.09, "open": 2.12, "dayLow": 2.084, "dayHigh": 2.16, "regularMarketPreviousClose": 2.09, "regularMarketOpen": 2.12, "regularMarketDayLow": 2.084, "regularMarketDayHigh": 2.16, "beta": 1.315, "forwardPE": -10.549999, "volume": 1559881, "regularMarketVolume": 1559881, "averageVolume": 1420458, "averageVolume10days": 1161660, "averageDailyVolume10Day": 1161660, "bid": 2.1, "ask": 2.15, "bidSize": 400, "askSize": 200, "marketCap": 312820160, "fiftyTwoWeekLow": 1.46, "fiftyTwoWeekHigh": 3.26, "priceToSalesTrailing12Months": 1.8255571, "fiftyDayAverage": 1.9926, "twoHundredDayAverage": 2.1283, "currency": "USD", "enterpriseValue": 494162464, "profitMargins": -0.37583, "floatShares": 143825784, "sharesOutstanding": 148256000, "sharesShort": 10792285, "sharesShortPriorMonth": 8941067, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0728, "heldPercentInsiders": 0.0269, "heldPercentInstitutions": 0.42796, "shortRatio": 7.93, "shortPercentOfFloat": 0.0746, "bookValue": -0.062, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -64401000, "trailingEps": -0.47, "forwardEps": -0.2, "enterpriseToRevenue": 2.884, "enterpriseToEbitda": -15.118, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XERS", "underlyingSymbol": "XERS", "shortName": "Xeris Biopharma Holdings, Inc.", "longName": "Xeris Biopharma Holdings, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8f5f7125-cc84-3c21-a68b-9d3090e24887", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.11, "targetHighPrice": 6.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.58, "targetMedianPrice": 4.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 87352000, "totalCashPerShare": 0.589, "ebitda": -32686000, "totalDebt": 268695008, "quickRatio": 1.707, "currentRatio": 2.371, "totalRevenue": 171356000, "revenuePerShare": 1.237, "returnOnAssets": -0.08545, "returnOnEquity": -6.1716304, "freeCashflow": -47130876, "operatingCashflow": -41186000, "revenueGrowth": 0.224, "grossMargins": 0.82903, "ebitdaMargins": -0.19075, "operatingMargins": -0.35053003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]